Delivered-To: tjphuhs@gmail.com Received: by 2002:adf:f3cb:0:b0:441:282b:bd with SMTP id g11csp1088729wrp; Thu, 23 Apr 2026 13:32:08 -0700 (PDT) X-Received: by 2002:a05:6214:3c8c:b0:8b1:f069:3fc6 with SMTP id 6a1803df08f44-8b1f06946f6mr263568526d6.40.1776976328168; Thu, 23 Apr 2026 13:32:08 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1776976328; cv=none; d=google.com; s=arc-20240605; b=Y2Jax3kBQgARfe0lZw1FBbhktPQz9479/fES3Mocsv5OTIzw8trYVL6kaipCMdO1R6 4et2lXLbuOFbxGxu4TcN9/uP+dmFGAzaGPxxrntLzSyebaz+YR7hk1IUNhsp5zUPdDts ged4joaA4ISuyR428SNzoQKokGmcBX7g8nl2xwOz2corq8Ck5iAR5I1Htn5VC41dHoBi TaBviYyG5e3IGYptdvn4EKkUSaWvyc7+stv37xb5svUme0Ipd1OscKLeJ/27psjQossP IENewimew+tqXp8OT4T/pFmeEcGSj1kRsP/VAcCQuPVUVgEm/8G2mOJkgEHIhW4QPnC/ XKIA== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=m69T6bVIPUH84GWmlOdzDhDmXBfwy1RcSLX30d5UuNQ=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=TszE5nHC5aDkJA5dQnsUba3cO7aYeVF4LurTS/fUVqNlKi0SGaBupPaVp+xJ94wLcT iPvARMzhMI+ALPRWYldGDmvtR8aRYbawO20u9x38MxgNEo9S3bToMjRjFVCcxwL/O8to YOzmgwWkkN9rI2fn3Hc+7lpjyQzwmhCT1oIun1mcu7JWK89NYeRnpOVQrmWXwYGnkVBI t1Suy8ZzlM66fzM5J/MgzMEzGUdW0YZM5tW9Iofa2Q552/EggLg8EvADQ2W8hYnnp0pK y9l/ApHo1AVvRYOIRLCS+C8eLj+/ZkT2pdl6jruVg+shygejnZPVQAmiKFVNfkBF4jnD pV5Q==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=b5gVga3c; dkim=pass header.i=@mailgun.org header.s=mg header.b=ehy1nCQD; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.9 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v59.v5375b7fa.use4.send.mailgun.net (v59.v5375b7fa.use4.send.mailgun.net. [159.112.244.9]) by mx.google.com with UTF8SMTPS id 6a1803df08f44-8b02ac8748esi221679636d6.159.2026.04.23.13.32.07 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Thu, 23 Apr 2026 13:32:08 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.9 as permitted sender) client-ip=159.112.244.9; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=b5gVga3c; dkim=pass header.i=@mailgun.org header.s=mg header.b=ehy1nCQD; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.9 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1776976327; x=1776983527; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=m69T6bVIPUH84GWmlOdzDhDmXBfwy1RcSLX30d5UuNQ=; b=b5gVga3ccpiJianhq24SfAzxxcmwuKiv2SR8f4y2Mo083y/rPt2eoBtr7vvWa7ZAQELyfHtIM1gwaz/o9rMgnrDgSozI6mwg/L/sNaqQjgagzXIp9P8ALO/EFDuCOLbbSudIa0PPlcjJDLr5DSEibV1psNv0g6OpQr1j4B/BjfM= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1776976327; x=1776983527; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=m69T6bVIPUH84GWmlOdzDhDmXBfwy1RcSLX30d5UuNQ=; b=ehy1nCQDRYF6A+P9F6evsJSlatLscQpp3khQJL3hvLOgtjtVyE+ZoP56AR6m6gLamcJtbGGBi4jhxAtVYFBTgslr2084lIp3oNhU8P/VTNL6cBzwgqG0v1xFKSoeAAH0S22BqTkjCVzQPnKFcJHeR2XU7LUl5DKT98OPFOGL0EE= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by b38ee3729bd75ad09098d04ddd021d6113a45d3593b1f5641120da7570bf8a07 with HTTP id 69ea81c6d5b68dcb1ad80077; Thu, 23 Apr 2026 20:32:06 GMT X-Mailgun-Sending-Ip: 159.112.244.9 X-Mailgun-Batch-Id: 69ea81c6967173881782d71c Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="6a2adca44694180ff91cd01e8609af1c8a39e4e88f58b583790684640254" Subject: Everyone's injecting peptides. Almost no one is measuring what they actually do. From: Bryan Johnson from Bryan Johnson To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260423203059.3.300cce05b4453b53@mg-d0.substack.com> Date: Thu, 23 Apr 2026 20:30:59 +0000 Feedback-Id: post-195281720:cat-post:pub-5008442:substack Sender: Bryan Johnson from Bryan Johnson References: In-Reply-To: Reply-To: Bryan Johnson from Bryan Johnson List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1776976326594", "is_freemail": "true", "post_audience": "everyone", "post_id": "195281720", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "5008442", "subdomain": "bryanjohns0n", "user_id": "273622398"} --6a2adca44694180ff91cd01e8609af1c8a39e4e88f58b583790684640254 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://bryanjohns0n.substack.com/p/everyones-= injecting-peptides-almost I'm stacking two peptides with opposite side effects and testing whether th= e downsides cancel while the benefits don't. Tirzepatide didn't work for me. I'm already top 1% on glucose control and b= ody composition, so the marginal upside was small. And even at 20% of the s= tarting dose (0.5 mg/week), my resting HR climbed 2=E2=80=933 bpm. Even gra= nting it might return to baseline in a couple weeks, not worth it. So I'm testing whether I can stack two peptides with opposite side effects = and get the best of both worlds. Tirzepatide: metabolic optimization, yet raises my HR and can disrupt my sl= eep. CJC-1295 (a GHRH agonist that drives my own GH and IGF-1): growth and repai= r, but can blunt my glucose control and cause insulin resistance. Opposite vectors on autonomic tone. Opposite vectors on glucose. On paper, = the side effects cancel but the benefits don't. That's my hypothesis. Now I'll measure it. Two CJC-1295 variants on the table: =E2=80=A2 DAC: weekly injection, extended half-life =E2=80=A2 No-DAC + Ipamorelin: daily, before bed The peptide community leans no-DAC, assuming it better preserves pulsatile = GH release, with fewer side effects. However, the published data on DAC is = better than the public consensus gives it credit for: sustained GHRH signal= ing without abolishing pulses, 7.5x overnight GH trough, >150% IGF-1 increa= se after two weekly doses at 30 =C2=B5g/kg. I'm starting with DAC, weekly dosing of the long-acting version, and monito= ring side effects closely. If they're intolerable, I'll switch to no-DAC + = Ipamorelin, daily. Here=E2=80=99s my protocol, taking it easy on the dose, since DAC peptides = are long acting: Week 1 1.2 mg CJC-1295 DAC Week 2 2.4 mg (or switch to no-DAC + Ipamorelin if side effects demand it) Weeks 3 and 4 2.4 mg CJC-1295 weekly + 0.25 mg tirzepatide, twice weekly Measuring everything: =E2=80=A2 Weekly blood: IGF-1, GH, GHRH, fasting glucose, insulin, HOMA-IR,= ApoA1, ApoB, prolactin, cortisol =E2=80=A2 Continuous CGM across all 4 weeks =E2=80=A2 Continuous core body temp (eCelsius capsule), weekly =E2=80=A2 Sleep, HR, HRV: 24/7 I'll post results as they arrive. Thanks for reading! Subscribe for free to receive new posts and support my = work. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9icnlhbmpvaG5= zMG4uc3Vic3RhY2suY29tL2FjdGlvbi9kaXNhYmxlX2VtYWlsP3Rva2VuPWV5SjFjMlZ5WDJsa0= lqb3lOek0yTWpJek9UZ3NJbkJ2YzNSZmFXUWlPakU1TlRJNE1UY3lNQ3dpYVdGMElqb3hOemMyT= 1RjMk16STJMQ0psZUhBaU9qRTRNRGcxTVRJek1qWXNJbWx6Y3lJNkluQjFZaTAxTURBNE5EUXlJ= aXdpYzNWaUlqb2laR2x6WVdKc1pWOWxiV0ZwYkNKOS5DanpZd2dKY0VEbHl5dHFJRjBHVmdXc2p= CMmY4WnBUT0FoTlNzOF9SVEFZIiwicCI6MTk1MjgxNzIwLCJzIjo1MDA4NDQyLCJmIjp0cnVlLC= J1IjoyNzM2MjIzOTgsImlhdCI6MTc3Njk3NjMyNiwiZXhwIjoyMDkyNTUyMzI2LCJpc3MiOiJwd= WItMCIsInN1YiI6ImxpbmstcmVkaXJlY3QifQ.xUJLwR4Dp7Em4o60GTxzb4eBNYJyo2CH8PTuP= KYd7HE? --6a2adca44694180ff91cd01e8609af1c8a39e4e88f58b583790684640254 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable = Everyone's injecting peptides. Almost no one is measuring what they actuall= y do.=3D""
I'm stacking two peptides with opposite side e= ffects and testing whether the downsides cancel while the benefits don't.
= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­

I'm stacking two peptides with opposite side effects and testi= ng whether the downsides cancel while the benefits don't.

Tirzepatide didn't work for me. I'm already top 1% on glucose control an= d body composition, so the marginal upside was small. And even at 20% of th= e starting dose (0.5 mg/week), my resting HR climbed 2–3 bpm. Even gr= anting it might return to baseline in a couple weeks, not worth it.<= br>
So I'm testing whether I can stack two peptides with opposite = side effects and get the best of both worlds.

Tirzepati= de: metabolic optimization, yet raises my HR and can disrupt my sleep.

CJC-1295 (a GHRH agonist that drives my own GH and IGF-1): = growth and repair, but can blunt my glucose control and cause insulin resis= tance.

Opposite vectors on autonomic tone. Opposite vec= tors on glucose. On paper, the side effects cancel but the benefits don't.<= /span>

That's my hypothesis. Now I'll measure it.
Two CJC-1295 variants on the table:
• DAC: we= ekly injection, extended half-life
• No-DAC + Ipamore= lin: daily, before bed

The peptide community leans no-D= AC, assuming it better preserves pulsatile GH release, with fewer side effe= cts. However, the published data on DAC is better than the public consensus= gives it credit for: sustained GHRH signaling without abolishing pulses, 7= =2E5x overnight GH trough, >150% IGF= -1 increase after two weekly doses at=20= 30 µg/kg.

I'm starting with DAC, weekly dosing of = the long-acting version, and monitoring side effects closely. If they're in= tolerable, I'll switch to no-DAC + Ipamorelin, daily.

H= ere’s my protocol, taking it easy on the dose, since DAC peptides are= long acting:

Week 1
1.2 mg CJC-1295 DA= C

Week 2
2.4 mg (or switch to no-DAC + = Ipamorelin if side effects demand it)

Weeks 3 and 4
2.4 mg CJC-1295 weekly + 0.25 mg tirzepatide, twice weekly

Measuring everything:
• Weekly blood= : IGF-1, GH, GHRH, fasting glucose, insulin, HOMA-IR, ApoA1, ApoB, prolacti= n, cortisol
• Continuous CGM across all 4 weeks
• Continuous core body temp (eCelsius capsule), weekly
• Sleep, HR, HRV: 24/7

I'll post res= ults as they arrive.

3D""

=
3D""


=

Thanks for reading! Subscribe for free to receive ne= w posts and support my work.

Ple= dge your support
<= /div>

Bryan Johnson is free today. But if you enjoyed this po= st, you can tell Bryan Johnson that their writing is valuable by pledging a= future subscription. You won't be charged unless they enable payments.

Pledge your support

=
&nb= sp;
3D""Share
=  
 
=
3D""Like
<= /td>
3D""Comment
3D""Restack=
 

© 2026 Bryan John= son
548 Market Street PMB 72296, San Francisco, CA 94104
Unsubscribe

3D"Start

3D"" --6a2adca44694180ff91cd01e8609af1c8a39e4e88f58b583790684640254--